Literature DB >> 9451976

The prime-boost concept applied to HIV preventive vaccines.

J L Excler1, S Plotkin.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9451976

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  27 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

4.  Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Authors:  J Benson; C Chougnet; M Robert-Guroff; D Montefiori; P Markham; G Shearer; R C Gallo; M Cranage; E Paoletti; K Limbach; D Venzon; J Tartaglia; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification.

Authors:  Yinghui Li; Yuxiao Huang; Jiao Liang; Zhikai Xu; Yan Shen; Ning Zhang; Zhongxiang Liu; Ya Zhao
Journal:  Mol Biol Rep       Date:  2013-03-01       Impact factor: 2.316

6.  Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

Authors:  I Ourmanov; M Bilska; V M Hirsch; D C Montefiori
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 9.  Novel directions in HIV-1 vaccines revealed from clinical trials.

Authors:  Jean-Louis Excler; Georgia D Tomaras; Nina D Russell
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 10.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.